MedTrace Logo

Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis

NCT04854837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-11-09

No results posted yet for this study

Summary

The FDA approved the antiviral drug remdesivir for use in adults for the treatment of COVID-19 requiring hospitalization.

There are only limited data about the safety of the drug in hemodialysed patents. Chronic kidney disease is a risk factor in COVID-19 for developing severe disease.

The aim of our investigation is to observe the safety of remdesivir among hemodialysed patients requiring hospitalization for COVID-19.

We are going to compare two group's data:

1. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted after 12/Apr/2021 - these patients received remdesivir.
2. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted before 12/Apr/2021 - these patients did not receive remdesivir.

Conditions

  • Covid19
  • End Stage Renal Failure on Dialysis

Interventions

DRUG

Remdesivir

Remdesivir treatment

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854837 on ClinicalTrials.gov